The New Neglected Diseases?

Policy Interventions Are Needed to Encourage CNS Drug Development

by Soeren Mattke, Erin Taylor, Lauren E. Hunter, Andrew W. Mulcahy

Download Free Electronic Document

FormatFile SizeNotes
PDF file 0.2 MB

Use Adobe Acrobat Reader version 7.0 or higher for the best experience.

Abstract

This paper evaluates the causes of the unmet need for investment in drugs targeting central nervous system diseases and discusses policy solutions to better align drug development with untreated disease burden. The authors' analysis suggests that current market forces are stacking the deck against development of drugs for common CNS disorders, as the expected returns on investment are lower and more uncertain than those for, say, targeted cancer drugs. They propose several policy changes that could steer investment into drugs for these "new neglected diseases" by reducing development cost and uncertainty and increasing expected revenue.

Research conducted by

The research underlying this paper was conducted in RAND Health, a division of the RAND Corporation.

This report is part of the RAND Corporation perspective series. RAND perspectives present informed perspective on a timely topic that address the challenges facing the public and private sectors. All RAND perspectives undergo rigorous peer review to ensure high standards for research quality and objectivity.

Permission is given to duplicate this electronic document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial purposes. Unauthorized posting of RAND PDFs to a non-RAND Web site is prohibited. RAND PDFs are protected under copyright law. For information on reprint and linking permissions, please visit the RAND Permissions page.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.